Nicole Bouvier

Add links
From Wikipedia, the free encyclopedia
Nicole Bouvier
Alma materIcahn School of Medicine at Mount Sinai
Williams College
Columbia University
Scientific career
InstitutionsIcahn School of Medicine at Mount Sinai
Mount Sinai Hospital

Nicole M. Bouvier is an American physician who is Professor of Medicine at Icahn School of Medicine at Mount Sinai. Her research considers the environmental and viral factors that impact respiratory transmission of influenza viruses.

Early life and education[edit]

Bouvier was a student of studio arts at Williams College. She moved to Columbia University as a medical student, where she completed her pre-medical coursework. She was a doctor of medicine at the Icahn School of Medicine at Mount Sinai, where she graduated with a Distinction in Research. She was a medical intern and resident at the Mount Sinai Hospital. After graduating, Bouvier was appointed a postdoctoral research fellow on the Physician-Scientist Research Training Program, where she worked alongside Peter Palese and started to study transmission of influenza that is resistant to oseltamivir. Bouvier makes use of guinea pig models.

Research and career[edit]

Bouvier was a clinical fellow in infectious disease at Mount Sinai Hospital from 2009 and appointed Assistant Professor in 2011.[citation needed] She has studied the impact of highly transmissible, highly pathogenic influenza viruses.[1][2]

In 2018, Bouvier told the Chicago Tribune, "It certainly is possible that a flu virus could again arise in the animal reservoir that is more pathogenic than the typical flu,".[3] She said that despite the risk, medical researchers were much better prepared to create vaccinations more quickly.[3] In 2019, she showed that louder talkers are more likely to spread airborne diseases.[4]

During the early days of the COVID-19 pandemic, Bouvier was involved with a study into the efficacy of convalescent plasma[5] as a treatment for COVID-19.[6][7][8][9] She studied the transfer of SARS-CoV-2 in both airborne dust and expiratory droplets.[10][11] She investigated the impact of face masks on the flow or airborne particles, and found it reduced the flow of particles considerably.[12][13] Even when the masks were poorly fitting (e.g. surgical and cloth face masks), the efficiency was around 70% for talking and 90% for coughing.[14]

Awards and honors[edit]

  • 2016 Sir William Osler Young Investigator Award[15]

Selected publications[edit]

  • Nicole M Bouvier; Peter Palese (12 September 2008). "The biology of influenza viruses". Vaccine. 26 Suppl 4: D49-53. doi:10.1016/J.VACCINE.2008.07.039. ISSN 0264-410X. PMC 3074182. PMID 19230160. Wikidata Q24620598.
  • Sima Asadi; Anthony S. Wexler; Christopher D. Cappa; Santiago Barreda; Nicole M. Bouvier; William D. Ristenpart (20 February 2019). "Aerosol emission and superemission during human speech increase with voice loudness". Scientific Reports. 9 (1). doi:10.1038/S41598-019-38808-Z. ISSN 2045-2322. PMC 6382806. PMID 30787335. Wikidata Q64263318.
  • Sima Asadi; Nicole Bouvier; Anthony S Wexler; William D Ristenpart (3 April 2020). "The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles?". Aerosol Science and Technology. 0 (0): 1–4. doi:10.1080/02786826.2020.1749229. ISSN 0278-6826. PMC 7157964. PMID 32308568. S2CID 215784311. Wikidata Q92061782.

References[edit]

  1. ^ Bouvier, N. M. (2012-06-01). "The Science of Security Versus the Security of Science". Journal of Infectious Diseases. 205 (11): 1632–1635. doi:10.1093/infdis/jis256. ISSN 0022-1899. PMC 3415856. PMID 22454475.
  2. ^ "Nicole M Bouvier | Icahn School of Medicine". Icahn School of Medicine at Mount Sinai. Retrieved 2021-11-26.
  3. ^ a b Thompson, Dennis. "Could the deadly 1918 flu pandemic happen again?". chicagotribune.com. Retrieved 2021-11-26.
  4. ^ "Loud Talkers Spread Disease". from Technology Networks. Retrieved 2021-11-26.
  5. ^ Tremblay, Douglas; Seah, Carina; Schneider, Thomas; Bhalla, Sheena; Feld, Jonathan; Naymagon, Leonard; Wang, Bo; Patel, Vaibhav; Jun, Tomi; Jandl, Thomas; Rahman, Farah (2020). "Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients". Cancer Medicine. 9 (22): 8571–8578. doi:10.1002/cam4.3457. ISSN 2045-7634. PMC 7537286. PMID 32945149.
  6. ^ "Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain". The Scientist Magazine®. Retrieved 2021-11-26.
  7. ^ Thomas, Katie; Weiland, Noah (2021-04-17). "The Covid-19 Plasma Boom Is Over. What Did We Learn From It?". The New York Times. ISSN 0362-4331. Retrieved 2021-11-26.
  8. ^ Nichols, Mackenzie (2020-06-09). "Meet Three Doctors Who Are Pioneering a Plasma Program for Coronavirus Treatment". Variety. Retrieved 2021-11-26.
  9. ^ Stanglin, Doug. "Plasma from recovered coronavirus patients boosts others' survival rate, study says". USA TODAY. Retrieved 2021-11-26.
  10. ^ Molteni, Megan. "A New Study Suggests a Possible Disease Vector: Germy Dust". Wired. ISSN 1059-1028. Retrieved 2021-11-26.
  11. ^ "Airborne viruses can spread on dust, non-respiratory particles". ScienceDaily. Retrieved 2021-11-26.
  12. ^ Rocheleau, Jackie. "Now, There Are Even More Reasons To Mask Up". Forbes. Retrieved 2021-11-26.
  13. ^ "Comparing face coverings in controlling expired particles: Surgical, N95 masks block most particles, study finds". ScienceDaily. Retrieved 2021-11-26.
  14. ^ Fell, Andy (2021-06-08). "Face Masks Block Expired Particles, Despite Leakage". UC Davis. Retrieved 2021-11-26.
  15. ^ "Awardees". Interurban Clinical Club. Retrieved 2021-11-26.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nicole_Bouvier&oldid=1179857189"